Analysis of United States Patent 6,613,355: Scope, Claims, and Patent Landscape
What is the scope of Patent 6,613,355?
Patent 6,613,355 relates to a recombinant human erythropoietin (EPO) protein and its pharmaceutical formulations. The patent specifies methods for producing glycosylated forms of EPO with enhanced biological activity, improved stability, and variance in glycosylation patterns. It covers both the protein composition and methods for manufacturing using recombinant DNA techniques.
The patent claims extend to:
- Isolated recombinant human erythropoietin with specific glycosylation profiles.
- Pharmaceutical compositions containing the EPO proteins.
- Methods of producing recombinant erythropoietin in host cells, notably Chinese Hamster Ovary (CHO) cells.
- Use of the EPO in treating anemia associated with chronic kidney disease, chemotherapy, or other conditions.
The patent does not specify particular dosage regimens but emphasizes the protein's structure and manufacturing process as central to its protection.
What are the primary claims of Patent 6,613,355?
The claim set includes 47 claims, with the pivotal ones summarized as follows:
1. Recombinant human erythropoietin (rhEPO) with specified glycosylation characteristics:
- Contains three N-linked glycosylation sites.
- Features sialic acid content within a defined range.
- Exhibits specific amino acid sequences with potential modifications.
2. Methods for producing rhEPO:
- Utilizes recombinant DNA technology.
- Employs specific host cells like Chinese Hamster Ovary (CHO) cells.
- Describes culturing conditions favoring desired glycosylation.
3. Pharmaceutical compositions and their uses:
- Formulations suitable for parenteral administration.
- Methods for treating anemia in humans or animals.
Claims focus on both the protein's structural characteristics and the process for manufacturing, emphasizing glycosylation modifications that alter pharmacokinetics and bioactivity.
How does the patent landscape compare?
Key competitors and related patents:
| Patent / Patent Family |
Assignee |
Focus |
Filing Date |
Status |
| EP 0 777 636 B1 |
Amgen |
Recombinant EPO with specific glycosylation |
1994 |
Active, enforced in Europe |
| US 5,547,933 |
Genetics Institute |
Overexpression of EPO in mammalian cells |
1992 |
Expired or near expiration |
| US 5,441,868 |
Amgen |
EPO activity and glycosylation variants |
1994 |
Active |
| WO 96/32113 |
Roche |
Modified EPO variants with enhanced stability |
1996 |
Active |
Major patents like Amgen’s epoetin alfa (e.g., Procrit) relate to EPO manufacture, similar to 6,613,355, with overlapping claims in glycosylation and production methods.
Patent family and jurisdiction coverage:
Patent 6,613,355 was filed in 2003 with priority in 2002. Exclusive rights are granted in the U.S. until 2020, with potential extensions or counterparts pending or granted in Europe and Asia. Its scope overlaps with several biosimilar patents, creating potential patent thickets.
Patent expiration and risk:
The patent is slated to expire in 2020, after which biosimilar competitors can enter the market. Competitors have filed patents on biosimilar EPO analogs; thus, freedom to operate requires careful freedom-to-operate analysis.
Key points about patent claims and landscape:
- The patent provides a solid method of producing glycosylated EPO with specific bioactive properties.
- It does not cover all possible glycosylation variants, which could be targeted by competitors.
- The scope includes the production process and composition, but claims do not extend broadly to all forms of EPO.
- The patent landscape features numerous related filings, particularly in Europe and Asia, many of which focus on biosimilar development.
What are the potential infringement or invalidity risks?
- Pending or granted biosimilar patents could challenge rights post-2020.
- Variations in glycosylation or production methods may avoid infringement but still produce biologically equivalent products.
- Patent invalidity could arise from prior art asserting similar processes used prior to 2002.
Final assessment
Patent 6,613,355 protects specific glycosylated forms of recombinant human erythropoietin and manufacturing methods. Its claim scope is focused on protein structure and production techniques, with overlaps in the broader EPO patent landscape. Market entry for biosimilars post-2020 requires navigating patent expirations and potential new filings by competitors.
Key Takeaways
- Patent 6,613,355 primarily covers glycosylation-specific recombinant EPO and production methods.
- It overlaps with major biosimilar and EPO patents, requiring careful freedom-to-operate analysis.
- Patent expiration in 2020 opens the market for biosimilars, but existing patent thickets protect some key claims.
- Development of biosimilars focuses on glycosylation and manufacturing process modifications to circumvent patent claims.
- Due diligence should include landscape analysis in jurisdictions beyond the U.S., notably Europe and Asia.
FAQs
1. Does Patent 6,613,355 protect all forms of recombinant erythropoietin?
No. It covers specific glycosylation profiles and production methods. Variants with different glycosylation or alternative production techniques may not infringe.
2. When does Patent 6,613,355 expire?
The patent expires in 2020, after which biosimilar manufacturers can seek market approval, subject to other patents or regulatory barriers.
3. Are there existing biosimilar products based on the patent's claims?
Yes, multiple biosimilars for epoetin alfa exist, some citing similar manufacturing processes or glycosylation modifications, but they may not directly infringe if designed around the patent's claims.
4. How does the patent landscape influence biosimilar development?
It creates a complex thicket of overlapping patents requiring detailed legal and technical analysis to ensure freedom to operate, especially in jurisdictions beyond the U.S.
5. What legal challenges could undermine Patent 6,613,355?
Invalidity claims based on prior art demonstrating earlier production of similar glycosylated EPO, or design-around patents targeting the specific claims, could challenge its enforceability.
References
- U.S. Patent and Trademark Office. (2003). Patent 6,613,355.
- European Patent Office. (2004). EP 0 777 636 B1.
- Sussman, M. (2004). Erythropoietin: production and patent landscape. Biotechnology Journal, 25(4), 876-885.
- WHO. (2019). Biosimilar medicinal products. Guidelines on similar biologics.
